Literature DB >> 3032882

Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles.

C E Hughes, W H Beggs.   

Abstract

Viability studies showed that fluconazole (UK-49,858) was strictly fungistatic in its activity against three strains of Candida species, whether tested against yeasts in stationary or early logarithmic phase. In this regard, fluconazole appears to offer no advantage over three other oral azole-containing agents, including ketoconazole, vibunazole (Bay n 7133), and ICI 153,066.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3032882     DOI: 10.1093/jac/19.2.171

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

Review 1.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

2.  Pharmacokinetics of fluconazole in patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  D Debruyne; J P Ryckelynck; M Moulin; B Hurault de Ligny; B Levaltier; M C Bigot
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

3.  Antagonism of the direct fungicidal action of miconazole by miconazole fungistasis.

Authors:  W H Beggs; I R LaSota; C E Hughes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-06       Impact factor: 3.267

Review 4.  Overview of medically important antifungal azole derivatives.

Authors:  R A Fromtling
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

Review 5.  Antifungal susceptibility testing.

Authors:  J H Rex; M A Pfaller; M G Rinaldi; A Polak; J N Galgiani
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

6.  Effect of prolonged fluconazole treatment on Candida albicans in diffusion chambers implanted into mice.

Authors:  Peter G Sohnle; Beth L Hahn
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

7.  Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans.

Authors:  E W van Etten; N E van de Rhee; K M van Kampen; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 8.  Invasive oesophageal candidiasis: current and developing treatment options.

Authors:  Jose A Vazquez
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Efficacy of fluconazole in the treatment of systemic fungal infections.

Authors:  D Milatovic; A Voss
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-05       Impact factor: 3.267

10.  Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection.

Authors:  M Ruhnke; A Eigler; I Tennagen; B Geiseler; E Engelmann; M Trautmann
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.